Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rodrigo Dienstmann

Showing results (21-30 of 175) with videos related to

Pageof 18
Sort By:
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 21, 2015
Overcoming Resistance to Anti-EGFR Therapy in Colorectal CancerRodrigo Dienstmann, Ramon Salazar, Josep Tabernero
Oncology (Williston Park, N.Y.)|March 19, 2015
Genomic testing in colorectal cancer: how much is enough?Rodrigo Dienstmann, Ramon Salazar, Josep Tabernero
Oncotarget|February 15, 2011
Targeting the PI3K/Akt/mTOR pathway--beyond rapalogsBen Markman, Rodrigo Dienstmann, Josep Tabernero
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 1, 2017
Pharmacokinetic/Pharmacodynamic Modeling for Drug Development in OncologyElena Garralda, Rodrigo Dienstmann, Josep Tabernero
Molecular Oncology|August 2, 2014
Optimal design of trials to demonstrate the utility of genomically-guided therapy: Putting Precision Cancer Medicine to the testRodrigo Dienstmann, Jordi Rodon, Josep Tabernero
Gastroenterology|January 24, 2020
Precision Therapy in RAS Mutant Colorectal CancerRodrigo Dienstmann, Kate Connor, Annette T Byrne, et al.
The Lancet. Oncology|December 4, 2018
Should next-generation sequencing testing be routinely used in metastatic colorectal cancer?Rodrigo Dienstmann, Aaron Ciner, Howard S Hochster
Future Oncology (London, England)|April 21, 2012
Panitumumab: a summary of clinical development in colorectal cancer and future directionsGuillem Argiles, Rodrigo Dienstmann, Elena Elez, et al.
Clinical Colorectal Cancer|July 7, 2011
Development of molecular biomarkers in individualized treatment of colorectal cancerLeticia De Mattos-Arruda, Rodrigo Dienstmann, Josep Tabernero
Annals of Hematology|August 11, 2021
Combination of novel molecular targeted agent plus R-CHOP-based regimen versus R-CHOP alone in previously untreated diffuse large B-cell lymphoma (DLBCL) patients: a systematic review and meta-analysisGuillermo Villacampa, Rodrigo Dienstmann, Francesc Bosch, et al.
Pageof 18

Showing results (21-30 of 175) with videos related to

Sort By:
Pageof 18
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 21, 2015
Overcoming Resistance to Anti-EGFR Therapy in Colorectal CancerRodrigo Dienstmann, Ramon Salazar, Josep Tabernero
Oncology (Williston Park, N.Y.)|March 19, 2015
Genomic testing in colorectal cancer: how much is enough?Rodrigo Dienstmann, Ramon Salazar, Josep Tabernero
Oncotarget|February 15, 2011
Targeting the PI3K/Akt/mTOR pathway--beyond rapalogsBen Markman, Rodrigo Dienstmann, Josep Tabernero
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 1, 2017
Pharmacokinetic/Pharmacodynamic Modeling for Drug Development in OncologyElena Garralda, Rodrigo Dienstmann, Josep Tabernero
Molecular Oncology|August 2, 2014
Optimal design of trials to demonstrate the utility of genomically-guided therapy: Putting Precision Cancer Medicine to the testRodrigo Dienstmann, Jordi Rodon, Josep Tabernero
Gastroenterology|January 24, 2020
Precision Therapy in RAS Mutant Colorectal CancerRodrigo Dienstmann, Kate Connor, Annette T Byrne, et al.
The Lancet. Oncology|December 4, 2018
Should next-generation sequencing testing be routinely used in metastatic colorectal cancer?Rodrigo Dienstmann, Aaron Ciner, Howard S Hochster
Future Oncology (London, England)|April 21, 2012
Panitumumab: a summary of clinical development in colorectal cancer and future directionsGuillem Argiles, Rodrigo Dienstmann, Elena Elez, et al.
Clinical Colorectal Cancer|July 7, 2011
Development of molecular biomarkers in individualized treatment of colorectal cancerLeticia De Mattos-Arruda, Rodrigo Dienstmann, Josep Tabernero
Annals of Hematology|August 11, 2021
Combination of novel molecular targeted agent plus R-CHOP-based regimen versus R-CHOP alone in previously untreated diffuse large B-cell lymphoma (DLBCL) patients: a systematic review and meta-analysisGuillermo Villacampa, Rodrigo Dienstmann, Francesc Bosch, et al.
Pageof 18